Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 13/20 | 0.65 |
| ▸ | PTGFR | P43088 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373144 | 0.92 | DHODH (0.65) | DHODHPTGFRTSHRPDE10A | |
| SCHEMBL2372133 | 0.90 | DHODH (0.54) | DHODHPTGFRPTGS2 | |
| SCHEMBL2373344 | 0.88 | DHODH (0.82) | DHODHPTGFRTSHRPDE10A | |
| SCHEMBL2373140 | 0.85 | DHODH (0.59) | DHODHPTGFRTSHRPDE10A | |
| SCHEMBL2372739 | 0.85 | DHODH (0.71) | DHODHPDE10A | |
| SCHEMBL2373103 | 0.85 | DHODH (0.70) | DHODHPTGFR | |
| SCHEMBL2372504 | 0.84 | DHODH (0.69) | DHODHPTGFRTSHRPDE10A | |
| SCHEMBL2372855 | 0.83 | DHODH (0.71) | DHODHPTGFRTSHRPDE10A | |
| SCHEMBL2373681 | 0.82 | DHODH (0.64) | DHODH | |
| SCHEMBL2464727 | 0.82 | DHODH (0.71) | DHODHPTGFRTSHRPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | DHODH 2190/4885PTGFR 703/4885PTGS2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.